Neurocrine Biosciences (NBIX) CTO Ratz reports initial stock and option grants
Rhea-AI Filing Summary
Neurocrine Biosciences executive Andrew Ratz has reported his initial equity holdings as Chief Technical Operations Officer. The Form 3 shows direct ownership of 1,018 shares of common stock and several equity awards that may convert into additional shares over time.
He holds restricted stock units tied to 3,997 and 5,640 underlying shares of common stock, which vest in annual installments through February 2029 and February 2030. He also holds incentive and non-qualified stock options covering 2,664 and 17,724 shares at an exercise price of $150.10 expiring in 2035, and 805 and 31,348 shares at $124.12 expiring in 2036, subject to monthly vesting schedules. These awards represent potential future ownership if vesting and exercise conditions are met.
Positive
- None.
Negative
- None.
Insider Trade Summary
7 transactions reported
Mixed
7 txns
Insider
Ratz Andrew
Role
Chief Technical Operations Off
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Restricted Stock Unit | -- | -- | -- |
| holding | Restricted Stock Unit | -- | -- | -- |
| holding | Incentive Stock Option | -- | -- | -- |
| holding | Non-Qualified Stock Option | -- | -- | -- |
| holding | Incentive Stock Option | -- | -- | -- |
| holding | Non-Qualified Stock Option | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Unit — 9,637 shares (Direct);
Incentive Stock Option — 3,469 shares (Direct);
Non-Qualified Stock Option — 49,072 shares (Direct);
Common Stock — 1,018 shares (Direct)
Footnotes (5)
- F1. Represents Restricted Stock Units (RSUs) remaining outstanding as of March 15, 2026. The RSU vested and settled as to 1/4 of the total units on February 3, 2026. The remaining RSUs vest annually at 1/4 of the total units subject to the award vesting on each of February 3, 2027, February 3, 2028, and February 3, 2029.
- F2. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
- F3. The RSUs will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030.
- F4. Represents option of which 1/4th of the shares underlying the option became vested and exercisable on February 3, 2026 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
- F5. Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 13, 2026 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does the Neurocrine Biosciences (NBIX) Form 3 for Andrew Ratz show?
It shows Andrew Ratz’s initial equity holdings as Chief Technical Operations Officer, including 1,018 common shares and multiple restricted stock unit and stock option awards that may convert into Neurocrine Biosciences common stock as they vest and, for options, if exercised.
What restricted stock units does Andrew Ratz report in his NBIX Form 3?
He reports two restricted stock unit awards representing 3,997 and 5,640 underlying shares of Neurocrine Biosciences common stock. Portions have begun vesting, with remaining units vesting annually in one-quarter increments through February 2029 and February 2030, subject to continued service and award terms.
What stock options does Andrew Ratz hold in Neurocrine Biosciences (NBIX)?
He holds incentive and non-qualified stock options over 2,664 and 17,724 shares at an exercise price of $150.10, expiring in 2035, and 805 and 31,348 shares at $124.12, expiring in 2036. These options vest over time, becoming exercisable in monthly installments.
How do Andrew Ratz’s RSUs convert into Neurocrine Biosciences (NBIX) common stock?
Each restricted stock unit represents a contingent right to receive one share of Neurocrine Biosciences common stock. Units vest in scheduled annual installments on specified February dates from 2027 through 2030, after which vested RSUs can settle into shares according to the award terms.
What is the vesting schedule for Andrew Ratz’s NBIX stock options?
For one option grant, one-quarter of the underlying shares vested on February 3, 2026, with the remainder vesting monthly at one-forty-eighth thereafter. For another, one-forty-eighth of the shares vested on March 13, 2026, with additional one-forty-eighth portions vesting each subsequent month.